Eversept Partners’s Cabaletta Bio CABA Stock Holding History

Eversept Partners’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-282,874	Closed	-$2.62M	–	65
2022 Q4	$2.62M	Sell	282,874 -277,592	-50%	-$1.01M	0.23%	46
2022 Q3	$364K	Buy	+560,466	New	+$675K	0.03%	65
2021 Q2	–	Sell	-76,849	Closed	-$853K	–	94
2021 Q1	$853K	Buy	+76,849	New	+$939K	0.06%	76

Other funds holding CABA

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Eversept Partners's CABA Position: Q1 2023 in Review

Eversept Partners sold out of Cabaletta Bio (CABA) in Q1 2023, closing a stake of 282,874 shares — an estimated $2.62M sold.

Eversept Partners first reported a position in CABA in Q1 2021 and held it in 3 quarters. The position peaked at $2.62M in Q4 2022. 71 funds tracked by Wall St. Rank hold CABA as of Q1 2023.

Eversept Partners reported no remaining Cabaletta Bio position as of Q1 2023 after selling out during the quarter.
Eversept Partners sold 282,874 Cabaletta Bio shares in Q1 2023, an estimated $2.62M.
Eversept Partners first reported a position in Cabaletta Bio in Q1 2021 and held it in 3 quarters.
Eversept Partners's Cabaletta Bio position peaked at $2.62M in Q4 2022.
71 funds tracked by Wall St. Rank held Cabaletta Bio as of Q1 2023.

Based on Eversept Partners's 13F filing for Q1 2023, filed 15 May 2023.